Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-089 · 5 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | Highest ABT-089 dose |
| 5 | ACTIVE_COMPARATOR | atomoxetine |
| 6 | PLACEBO_COMPARATOR | placebo |
| Name | Type | Description |
|---|---|---|
| ABT-089 | DRUG | Subjects will take up to 80 mg daily for 24 months |
| Placebo | DRUG | Subjects will take one or two placebos once daily for the duration of the study. |
| atomoxetine | DRUG | Subjects will take 10, and/or 18 and/or 25 mg atomoxetine tablets once daily for 8 weeks. |
Inclusion Criteria: * The subject was randomized into Study M10-346 and completed the study. * Female subjects of childbearing potential must have a negative urine pregnancy test at screening and baseline and agree to comply with applicable contraceptive requirements. * Male subjects must agree to ...
ABT-089 is an investigational small molecule being studied for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and children. It is in Phase 2 clinical development and has not been approved by the FDA. The drug is being developed by AbbVie Inc.
ABT-089 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The drug is an investigational small molecule in Phase 2 clinical trials for Attention-Deficit/Hyperactivity Disorder (ADHD).
ABT-089 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. All four completed clinical trials for ABT-089 were Phase 2 studies, with no active trials currently ongoing.
ABT-089 has completed four Phase 2 clinical trials in the United States. These include NCT00443391 and NCT00640185 in adults with ADHD, NCT00640419 in children with ADHD, and NCT00686933, a long-term safety study in adults. All trials are completed with a total enrollment of 676 participants.
ABT-089 is the primary name for this investigational drug. No alternative names have been reported in clinical trial records. It is a small molecule being studied for Attention-Deficit/Hyperactivity Disorder (ADHD) and is not the same as other marketed ADHD medications.